HD-OPM Archive
Topics › Cancer

EVITA: vitamin C cut deaths in early blood cancers, 11 vs 24, in a small phase 2 trial

Louis Nervegna · Oct 28, 2026 · ♥ 13 reactions · 1 comments · original Facebook post
CancerSupplements & vitamins
↻ This is a repost. The main version (highest ranked) is EVITA trial: vitamin C lowered deaths in clonal blood conditions (exploratory result) · Sep 29, 2026.
AI summary & key facts

In the EVITA phase 2 randomized trial of oral vitamin C in clonal cytopenia and lower-risk myeloid malignancies, the vitamin C group had a 65% lower risk of death than placebo (11 vs 24 deaths) and fewer serious adverse events. The rationale involves vitamin C supporting TET2 in blood stem cells. The trial is small and not about heart disease.

In a small recently published randomized trial (EVITA), vitamin C supplements improved survival and reduced adverse events in patients with particular clonal diseases, specifically pre-cancerous blood conditions and low-risk blood cancers.

Over the course of the trial, the vitamin C group had a 65% lower risk of death, compared to the placebo group. There were 11 deaths in the vitamin C arm, compared to 24 deaths in the control arm. In the vitamin C group, only 33% experienced a serious adverse event, compared to 57% in the placebo group.

One can speculate that this trial might be relevant to anyone with clonal diseases, which are common with advancing age (and typically go undiagnosed). This is a big unproven leap given the limited evidence, but there is substantial biological plausibility. These clonal diseases seem to play a role in CVD, e.g. clonal hematopoiesis of indeterminate origin (CHIP). Search the group for the tag #chipHD to learn more. Also see this recent post: facebook.com/share/v/19N5HCuCap.

Note that overall survival and adverse events were an exploratory endpoint in this trial. The increase in overall survival and decrease in adverse events occurred in spite of the fact that there was no significant difference in the clonal growth rate between the vitamin C group and the placebo group over the 12 month period of the trial, which was the primary endpoint.

The researchers specifically chose to test vitamin C because it acts as a cofactor to restore TET2 enzyme function.

TET2 is a crucial enzyme that acts as a regulator of DNA methylation, helping control how stem cells develop into mature blood cells. When TET2 is mutated or deficient— which happens frequently with aging— blood stem cells begin to clone themselves abnormally instead of maturing properly. In the context of cardiovascular disease and low-risk blood cancers, this loss of TET2 function triggers systemic inflammation, accelerating plaque buildup in the arteries and promoting pre-cancerous blood conditions.

Additionally, the TET2 biological mechanism applies more broadly to somatic mutations seen across many aging individuals.

TET2 also plays a role in the aging process itself by controlling age-related DNA methylation in cells. See this post: ↪ Vitamin C may reprogram epigenetics in skin cells, a lab finding on skin aging.

Link to journal paper:

Paper · Cancer · 2026Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial.Conclusion: These findings suggest oral VitC as a safe, biologically active intervention in patients with early-stage myeloid malignancies and precursor conditions. A phase 3 trial is warranted.pmc.ncbi.nlm.nih.gov

Below is a summary of the trial from Gemini AI:

Oral high-dose vitamin C supplementation (1000 mg/day) in patients with clonal cytopenia of undetermined significance (CCUS) or lower-risk myeloid malignancies is safe and biologically active, though it did not significantly reduce the median clonal growth rate over 12 months in the phase 2 EVITA trial.

Key Findings of the EVITA Trial

#vitamincHD #cancerHD #ccusHD #myeloidmalignancyHD #clonaldiseasesHD #chipHD #tet2HD #somaticmutationsHD #agingHD #longevityHD

Research cited

In early blood cancer, people taking vitamin C died at less than half the rate.

Vitamin C has a mixed record in cancer. Two trials in 1979 and 1985 gave 10 grams a day to 250 people with advanced cancer and found no benefit. Interest returned in 2017, when studies showed that blood stem cells hold unusually high levels of vitamin C, which helps an enzyme called TET2 keep them in check. TET2 is often mutated in early blood cancers, and in mice, vitamin C mimicked restoring it and slowed leukemia.

That left open whether a modest daily dose could help at the earliest stages. The EVITA trial randomized 109 adults, most in their 70s, whose mutated blood stem cells were causing low blood counts, either a pre-cancer state or a lower-risk early blood cancer. They took 1,000 mg of vitamin C or a placebo daily for 12 months, then were followed for nearly three years.

57% started with low or deficient vitamin C, and the supplement raised blood levels by about 80% while placebo levels barely moved.

The main goal was missed, since the mutated cells grew at a similar slow pace in both groups, but inflammatory signals such as IL-6 rose on placebo and not on vitamin C.

During the treatment year, 33% on vitamin C had a serious health event compared with 57% on placebo, and pneumonia struck 2% versus 15%. Over follow-up, 11 of 55 people on vitamin C died compared with 24 of 54 on placebo, a gap that held after adjusting for differences between the groups. Infections were the leading cause of death.

A separate mouse preprint from UT Southwestern suggests why low levels might matter. Removing vitamin C from blood-forming cells was enough on its own to cause leukemia, leukemia cells soaked up vitamin C and drained it from the blood, and restoring it in mice with established leukemia extended survival.

Taken together, vitamin C did not shrink the abnormal cells, but people with these conditions often run low, and correcting that came with fewer serious illnesses and deaths. For anyone with one of these diagnoses, vitamin C status is a reasonable question to raise with a hematologist, since 1,000 mg a day is inexpensive and was well tolerated here.

The survival result was an exploratory analysis added outside the trial's original plan, in a small study not designed to test it. The groups differed at the start, the benefit looked smaller in older patients, and supplement use after the first year was not controlled. The findings do not apply to advanced cancers or healthy people.

References
Mikkelsen SU et al., Cancer, 2026
Wijshake T et al., bioRxiv (preprint), 2026
Agathocleous M et al., Nature, 2017
Cimmino L et al., Cell, 2017
Creagan ET et al., New England Journal of Medicine, 1979
Moertel CG et al., New England Journal of Medicine, 1985

May be an image of text
← newer: A healthy glycocalyx does not protect against high LDL/ApoB,older: Blood p-Tau 217 testing can flag Alzheimer's pathology years →